- Rockley reaches new milestone in its efforts to transform
consumer health monitoring through non-invasive biomarker
sensing
- Shipment of VitalSpex™ Pro technology expands list of
Rockley’s global consumer electronics customers
- Leading wearables manufacturer to explore integration of new
class of optical biomarker sensors into next-generation consumer
devices
Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”), a
global leader in photonics-based health monitoring and
communications solutions, today announced that one of its tier-1
consumer wearables customers has begun an evaluation program using
Rockley’s photonics-based sensing technology, which was recently
shipped to the customer. Under the evaluation program, Rockley’s
comprehensive non-invasive biomarker measurement solutions will be
assessed for potential integration into the customer’s future
wearable products. The tier-1 customer adds to Rockley’s growing
list of global consumer electronics manufacturers to receive
shipments of Rockley’s VitalSpex™ Pro technology, which is expected
to enable the non-invasive measurement of alcohol, glucose, and
lactate from a wrist-worn device.
Dr. Andrew Rickman, chairman and chief executive officer of
Rockley, said, “We are excited about entering this new phase of
development — and about strengthening our relationship with one of
the world’s leading consumer wearables companies. This evaluation
program further demonstrates the immense potential of our
biosensing platform, and it marks an important milestone in the
road to integrating our non-invasive biomarker sensing into
consumer devices. By working with this customer, and with other
customers, our platform’s ability to deliver unique insights into a
person’s health and well-being could potentially define the next
generation of consumer health monitoring and help realize the goal
of improving people’s health.”
The consumer wearables customer is one of twelve consumer
electronics customers actively contracted with Rockley. By
incorporating Rockley’s advanced biosensing technology,
Rockley-powered wearable devices could enable the routine, near
real-time, non-invasive monitoring of a wide range of biomarkers,
including core body temperature, blood pressure, heart rate, blood
oxygen, body hydration, alcohol, lactate, and glucose, among
others.
More information about Rockley’s digital health monitoring
solution is available here:
https://rockleyphotonics.com/biomarker-sensing
About Rockley Photonics
A global leader in photonics-based health monitoring and
communications solutions, Rockley Photonics is developing a
comprehensive range of photonic integrated circuits and associated
modules, sensors, and full-stack solutions. From next-generation
sensing platforms specifically designed for mobile health
monitoring and machine vision to high-speed, high-volume solutions
for data communications, Rockley is laying the foundation for a new
generation of applications across multiple industries. Rockley
believes that photonics will eventually become as pervasive as
micro-electronics, and it has developed a platform with the power
and flexibility needed to address both mass markets and a wide
variety of vertical applications.
Formed in 2013, Rockley is uniquely positioned to support
hyper-scale manufacturing and address a multitude of high-volume
markets. Rockley has partnered with numerous tier-1 customers
across a diverse range of industries to deliver the complex optical
systems required to bring transformational products to market.
To learn more about Rockley, visit rockleyphotonics.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release that are not historical facts
constitute “forward-looking statements” for purposes of the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include statements
regarding Rockley’s future expectations, beliefs, plans,
objectives, and assumptions regarding future events or performance.
The words “accelerate,” “advance,” “anticipate,” “believe,” “can,”
“capability,” “continue,” “could,” “develop,” “enable,” “estimate,”
“eventual,” “expand, “expect,” “focus,” “forward,” “future,”
“goal,” “intend,” “may,” “might,” “opportunity,” “outlook,” “plan,”
“possible,” “position,” “potential,” “predict,” “project,”
“revolutionize,” “seem,” “should,” “trend,” “vision,” “will,”
“would” or other terms that predict or indicate future events,
trends, or expectations, and similar expressions or the negative of
such expressions may identify forward-looking statements, but the
absence of these words or terms does not mean that a statement is
not forward-looking. Forward-looking statements in this press
release include, but are not limited to, statements regarding the
following: (a) the potential of Rockley’s sensing platform to
provide real-time insights about a variety of health conditions and
enable the early detection of disease states through routine, near
real-time, non-invasive monitoring of a wide range of biomarkers;
(b) our platform’s ability to potentially define the next
generation of consumer health monitoring and help realize the goal
of improving people’s health; (c) Rockley’s belief that photonics
will eventually become as pervasive as micro-electronics; and (d)
Rockley’s potential to support hyper-scale manufacturing, address a
multitude of high-volume markets, and deliver the complex optical
systems required to bring transformational products to market.
Forward-looking statements are subject to several risks and
uncertainties (many of which are beyond Rockley’s control) or other
assumptions that may cause actual results or performance to differ
materially from those expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, the following: (i) Rockley’s ability to achieve
customer acceptance and commercial production of its products and
technology, including in a timely and cost-effective manner; (ii)
Rockley’s ability to achieve customer design wins and convert
memoranda of understanding and development contracts into
production contracts; (iii) risks related to purchase orders,
including the lack of long-term purchase commitments, the
cancellation, reduction, delay, or other changes in customer
purchase orders, and if and to the extent customers seek to enter
into licensing arrangements in lieu of purchases; (iv) Rockley’s
history of losses and need for additional capital and its ability
to access additional financing to support its operations and
execute on its business plan, as well as the risks associated
therewith; (v) legal and regulatory risks; (vi) risks associated
with its fabless manufacturing model and dependency on third-party
suppliers; (vii) Rockley’s reliance on a few significant customers
for a majority of its revenue and its ability to expand and
diversify its customer base; (viii) Rockley’s financial
performance; (ix) the impacts of COVID-19 on Rockley, its customers
and suppliers, its target markets, and the global economy; (x)
Rockley’s ability to successfully manage growth and its operations
as a public company; (xi) fluctuations in Rockley’s stock price and
Rockley’s ability to maintain the listing of its ordinary shares on
the NYSE; (xii) Rockley’s ability to anticipate and respond to
industry trends and customer requirements; (xiii) changes in the
current and future markets in which Rockley is or may be engaged;
(xiv) risks related to competition and intellectual property; (xv)
market opportunity and demand for Rockley’s products and
technology, as well as the customer products into which Rockley’s
products and technology are incorporated; (xvi) risks related to
international operations; (xvii) risks related to cybersecurity,
privacy, and infrastructure; (xviii) risks related to financial and
accounting matters; (xix) general economic, financial, political,
and business conditions, both domestic and foreign; and (xx)
Rockley’s ability to realize the anticipated benefits of strategic
partnerships, as well as other factors described under the heading
“Risk Factors” in Rockley’s annual report on Form 10-K, and in
other documents Rockley files with the Securities and Exchange
Commission in the future.
The forward-looking statements contained in this press release
are based on various assumptions, whether or not identified in this
press release, and on Rockley’s current expectations, beliefs, and
assumptions and are not predictions of actual performance. If any
of these risks or uncertainties materialize, or should any of these
assumptions prove incorrect, actual results may differ materially
from those discussed in or implied by these forward-looking
statements. There can be no assurance that future developments
affecting Rockley will be those that have been anticipated. These
forward-looking statements speak only as of the date hereof and
Rockley does not intend to update or revise any forward-looking
statements, whether because of new information, future events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220616005041/en/
Media Debra Raine Rainemakers Telephone: +1 415-349-7432 Email:
rockleyphotonics@rainemakers.com
Investors Gwyn Lauber Rockley Photonics Telephone: +1
626-995-0001 Email: investors@rockleyphotonics.com
Rockley Photonics (NYSE:RKLY)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Rockley Photonics (NYSE:RKLY)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
